P-glycoprotein expression: Critical determinant in the response to osteosarcoma chemotherapy
P-glycoprotein expression: Critical determinant in the response to osteosarcoma chemotherapy
复制标题
DOI：
10.1093/jnci/89.22.1706
复制
发表时间：
1997-11-19
期刊：
影响因子：
--
通讯作者：
Ling, V
中科院分区：
文献类型：
--
作者：
Chan, HSL;Grogan, TM;Ling, V
背景：只有不到20%的骨癌患者接受手术治疗后治愈。即使采用目前最好的治疗方法，即手术联合化疗，也只有60%-80%的非转移性骨癌患者和10%的转移性骨癌患者治愈。到目前为止，尚未确定无应答亚组治疗失败的原因。据推测，P-糖蛋白，赋予多药耐药，可能是原因。我们试图确定P-糖蛋白的表达是否与骨肉瘤的不良治疗结果有关。研究方法：在一项回顾性研究中，我们将1980年至1989年诊断为骨肉瘤的62例连续临床分期患者的P-糖蛋白表达与常规化疗的结果相关联。结果：27例患者P-糖蛋白过表达，34例患者P-糖蛋白阴性。并且在来自一名患者的样品中表达不明确。中位随访时间为8.9年，34例肿瘤不表达P-糖蛋白的患者的无复发率明显高于27例肿瘤表达该蛋白的患者（87%对0%; P
Background: Fewer than 20% of patients with bone cancer who are treated with surgery alone are cured. Even with the best current treatment, surgery combined with chemotherapy, only 60%-80% of patients with nonmetastatic bone cancer and 10% of patients with metastatic bone cancer are cured. Thus far, the reason for treatment failure in the nonresponding subset has not been identified. It has been hypothesized that P-glycoprotein, which confers multidrug resistance, might be the cause. We sought to determine whether the expression of P-glycoprotein is associated with poor treatment outcome in osteosarcoma. Methods: In a retrospective study, we correlated P-glycoprotein expression with the outcome of conventional chemotherapy in 62 consecutive, clinically staged patients diagnosed as having osteosarcoma between 1980 and 1989. Results: P-glycoprotein was overexpressed in 27 patients but not in another 34 patients. and expression was ambiguous in the sample from one patient. At a median follow-up of 8.9 years, the 34 patients whose tumors did not express P-glycoprotein had significantly better relapse-free rates than the 27 subjects whose tumors expressed the protein (87% versus 0%; P